Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Daiichi Sankyo
Citi
Queensland Health
Express Scripts
Harvard Business School
Chinese Patent Office
Covington
Farmers Insurance
Julphar

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202236

« Back to Dashboard

NDA 202236 describes DYMISTA, which is a drug marketed by Mylan Speciality Lp and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug and one Paragraph IV challenge. Additional details are available on the DYMISTA profile page.

The generic ingredient in DYMISTA is azelastine hydrochloride; fluticasone propionate. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the azelastine hydrochloride; fluticasone propionate profile page.
Summary for 202236
Tradename:DYMISTA
Applicant:Mylan Speciality Lp
Ingredient:azelastine hydrochloride; fluticasone propionate
Patents:3
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 202236
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DYMISTA azelastine hydrochloride; fluticasone propionate SPRAY, METERED;NASAL 202236 NDA Meda Pharmaceuticals Inc. 0037-0245 0037-0245-06 1 BOTTLE, SPRAY in 1 BOX (0037-0245-06) > 28 SPRAY, METERED in 1 BOTTLE, SPRAY
DYMISTA azelastine hydrochloride; fluticasone propionate SPRAY, METERED;NASAL 202236 NDA Meda Pharmaceuticals Inc. 0037-0245 0037-0245-23 1 BOTTLE, SPRAY in 1 BOX (0037-0245-23) > 120 SPRAY, METERED in 1 BOTTLE, SPRAY

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SPRAY, METERED;NASALStrengthEQ 0.125MG BASE/SPRAY;0.05MG/SPRAY
Approval Date:May 1, 2012TE:ABRLD:Yes
Regulatory Exclusivity Expiration:Feb 20, 2018
Regulatory Exclusivity Use:NEW PATIENT POPULATION
Regulatory Exclusivity Expiration:Aug 20, 2018
Regulatory Exclusivity Use:PEDIATRIC EXCLUSIVITY
Patent:➤ SubscribePatent Expiration:Feb 29, 2024Product Flag?Substance Flag?Delist Request?Y

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Moodys
Merck
Cerilliant
Cantor Fitzgerald
Fuji
Citi
UBS
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot